Posts

10K 2018 Financials NLBS 1252

Summary: NutraLife BioSciences, Inc. (“NLBS” or the “Company”), a manufacturer and distributor of CBD and nutritional spray products and tinctures announces its financial results for the year ended December 31, 2018 with revenue of $3,711,327 compared to $1,790,168 for the year ended December 31, 2017.

NutraLife Biosciences Inc. (“NutraLife Biosciences” or “NLBS”), (OTC Markets OTCQB: NLBS), a developer, manufacturer and distributor of nutraceutical and CBD products today announced the filing of its Form 10-K and financial results for the fiscal year ended December 31st, 2018.

Highlights from the Company’s financial results reported in its Form 10-K for the year ended December 31, 2018 include:

  • Sales increased to $3,711,327 for the year ended December 31, 2018 compared to $1,790,168 for the year ended December 31, 2017, an increase of approximately 107.3%.
  • Cost of sales was $2,211,039 compared to $1,055,042 for the years ended December 31, 2018 and 2017, respectively, or a 109.6% increase.
  • Net Loss decreased approximately 91.3% to $2,074,537 in the year ended December 31, 2018 from $23,629,117 in 2017.
  • Gross margin for the year ended December 31, 2018 was $1,500,288, a 104.1% increase over the year ended December 31, 2017.
  • For the year ended December 31, 2018, Loss from Operations decreased approximately 90.6% from 2017 ($1,906,044 compared to $20,289,624).
  • Cash provided by financing activities for the year ended December 31, 2018 decreased approximately 19.4% from 2017.
  • General and Administrative Expenses increased for the year ended December 31, 2018 to $2,070,714 or approximately 17.6% from $1,760,148 for the year ended December 31, 2017.
  • New Debt increased in the year ended December 31, 2018 to $480,000.
  • The annual loss for the year ended December 31, 2018 includes approximately $1,200,000 of non-cash charges relating to the conversion of debt and shares issued for services.

“NutraLife BioSciences, Inc. (“NLBS”, “we”, or “us”) is pleased to report its 2018 year-end financials and announced that its revenues have improved more than approximately 107% over 2017,” said Edgar Ward, NLBS’s CEO. “The notable increase in our revenue is a direct result of increased business and reorder production over this past year. NLBS’s net loss reflects non-recurring additional paid in capital as non-cash and is in the form of stock issued at fixed prices for debt conversions and for services rendered throughout the year. NLBS has entered phase two of its build out of its new 20,000 square foot manufacturing facility in Deerfield Beach, Florida. We look forward to the increased capacity and efficiencies that will come with our new state of the art facility. We plan to move into the new facility by the end of the second quarter.”

The financial information contained in this press release is qualified in its entirety by the audited financial statements and financial statement notes included in the Company’s Form 10-K for the year ended December 31, 2018, filed with the Securities & Exchange Commission on April 2, 2019.


Forward Looking Statements

This press release contains statements of a forward-looking nature. These statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. You can identify these forward-looking statements by words or phrases such as “may,” “will,” “except,” “anticipate,” “aim,” “estimate,” “intend,” “plan,” “believe,” “is/are likely to,” “future” or other similar expressions. NutraLife BioSciences, Inc. (“NLBS” or the “Company”) has based these forward-looking statements largely on the Company’s current expectations and projections about future events and financial trends that the Company believes may affect Company’s financial condition, results of operations, business strategy and financial needs. There is no assurance that the Company’s current expectations and projections are accurate. All forward-looking statements in this press release are based on information available to the Company on the date hereof. These statements involve known and unknown risks, uncertainties and other factors that may cause the Company’s actual results to differ materially from those implied by the forward-looking statements. More detailed information about these risk factors are set forth in the Company’s filings with the Securities and Exchange Commission, including, but not limited to, those risks and uncertainties listed in the Section entitled “Risk Factors,” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2018 filed with the Securities and Exchange Commission on April 2, 2019. The Company operates in a rapidly evolving environment. New risk factors emerge from time to time, and it is impossible for the Company’s management to predict all risk factors, nor can the Company assess the impact of all factors on Company’s business or the extent to which any factor, or combination of factors, may cause actual results to differ from those contained in any forward-looking statement. The Company does not undertake any obligation to update or revise the forward-looking statements except as required under applicable law.

NutraLife Biosciences Encouraged By CVS Health Corporation’s Decision to Distribute CBD at 800 Stores in the U.S.

Summary: CVS Health Corp. announces it will carry cannabidiol, also known as CBD, the non-psychoactive derivative of hemp in about 800 stores across the US.

NutraLife Biosciences, Inc. (“the Company” or “NutraLife”) (OTCQB: NLBS) notes current trends in the retail space including CVS Health Corp.’s announcement that it will carry products containing CBD derived from hemp in about 800 of its U.S. drugstores.

NutraLife announces new additions to its NutraHempCBD product line with a micro shot CBD twists in 5 of its signature formulations including; sleep, pain, stress, weight, and sleep. The NutraHempCBD twists are designed for on-the-go convenience and set to launch on April 15 of this year.

“It is encouraging to see that mainstream retail giants like CVS are offering hemp derived CBD products to consumers,” said Edgar Ward, Founder and Chief Executive Officer of NutraLife Biosciences.

NutraHempCBD is in the last stages of development of its CBD micro shot twist products offering a single serving of CBD plus other clinically tested ingredients for daily health and wellness applications. The launch of the CBD micro shot twists in its 5 signature formulations demonstrate evolving and innovative retail-ready nutraceutical and industrial hemp CBD products.

Since 2013, the Company has engaged in the manufacturing and distribution of nutraceutical products for both branded and private label sales. In 2017, the Company launched its industrial hemp CBD products for private label sales and its own NutraHempCBD brand. The Company’s products are sold at a variety of retailers including drugstores.

According to reports, executives on Curaleaf’s earnings conference call said CVS would begin to carry its Curaleaf hemp lotions and transdermal patches in about 800 stores across 10 U.S. states. Chief Executive Officer of CVS, Joe Lusardi said Wednesday that the products would be available in stores by this Friday and through the CVS website “soon.”

On December 20, 2018, the U.S. Food and Drug Administration completed an evaluation of three generally recognized as safe (GRAS) notices for hemp seed-derived food ingredients. The agency concluded that hulled hemp seed (GRN765), hemp seed protein powder (GRN771), and hemp seed oil (GRN778) are GRAS as they contain only trace amounts of THC and CBD. The GRAS notices are for three different hemp seed-derived ingredients for certain uses including adding them as a source of protein, carbohydrates, oil, and other nutrients to beverages (juices, smoothies, protein drinks, plant-based alternatives to dairy products), soups, dips, spreads, sauces, dressings, plant-based alternatives to meat products, desserts, baked goods, cereals, snacks and nutrition bars. The FDA’s complete release of the GRAS notice can be read here.

NutraLife BioSciences is a fully reporting company with a class of securities registered with the U.S. Securities and Exchange Commission (“SEC”). NLBS recently announced its financial results for the three (3) and nine (9) month period ended September 30, 2018 with revenue of $1,062,146 and $2,870,462 respectively compared to $652,385 and $1,027,727 for the three (3) and nine (9) month period ended September 30, 2017. NLBS’s filings with the SEC can be viewed at www.sec.gov. NLBS’s CBD products and information about the Company’s direct sales program can be found online at https://nutrahempcbd.com and by following the company on Instagram.

* The statements in this Release have not been evaluated by the Food and Drug Administration.

* NutraLife’s CBD and nutraceutical products are not intended to diagnose, treat, cure or prevent any disease.

* NutraLife is not affiliated with and has no association with Curaleaf or CVS Health Corp.

Forward-Looking Statements

This communication from NutraLife BioSciences, Inc. (the “Company”) contains statements of a forward-looking nature. These statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. You can identify these forward-looking statements by words or phrases such as “may,” “will,” “except,” “anticipate,” “aim,” “estimate,” “intend,” “plan,” “believe,” “is/are likely to,” “future” or other similar expressions. The Company has based these forward-looking statements largely on the Company’s current expectations and projections about future events and financial trends that the Company believes may affect Company’s financial condition, results of operations, business strategy, and financial needs. There is no assurance that the Company’s current expectations and projections are accurate. All forward-looking statements in this press release are based on information available to the Company on the date hereof. These statements involve known and unknown risks, uncertainties and other factors that may cause the Company’s actual results to differ materially from those implied by the forward-looking statements. More detailed information about these risk factors are set forth in the Company’s filings with the Securities and Exchange Commission, including, but not limited to, those risks and uncertainties listed in the section entitled “Risk Factors,” in the Company’s Annual Report on Form 10-K with the Securities and Exchange Commission on April 17, 2018. The Company operates in a rapidly evolving environment. New risk factors emerge from time to time, and it is impossible for the Company’s management to predict all risk factors, nor can the Company assess the impact of all factors on Company’s business or the extent to which any factor, or combination of factors, may cause actual results to differ from those contained in any forward-looking statement. The Company does not undertake any obligation to update or revise the forward-looking statements except as required under applicable law.

Contact:

NutraLife Biosciences, Inc.
6601 Lyons Road
Suite L-6 Coconut Creek
FL  33073 Telephone
Telephone: 888-509-8901
www.Nutralifebiosciences.com

NutraLife Biosciences, Inc. (OTCQB: NLBS) Receives Contract to Provide Its Technologies and Delivery System for Pharmaceutical Products by cGMP Pharmacy

NutraLife Biosciences enters into a contract with a cGMP pharmacy to provide its technologies and a delivery system for pharmaceutical products.

NutraLife Biosciences, Inc. (“the Company” or “NutraLife”) (OTCQB: NLBS) announces it has signed an agreement with Orlando Pharmacy, a USP 797 compliant compounding pharmacy, to provide its technologies and an innovative delivery system for pharmaceutical products

Craig Sicinski, a pharmacist and owner of Orlando Pharmacy and a board advisor to BioHealth Technologies, a CBD and nutraceutical AI PAAS (Platform As A Service) company commented, “We are thrilled to have this new agreement with with NutraLife and to use its technologies and delivery system in our pharmaceutical products. Our shared goal is to discover new innovations within the life sciences space.”

Edgar Ward, CEO and Founder of NutraLife Biosciences stated, “this is a great opportunity for us to expand our technologies and delivery systems into the Pharmaceutical marketplace. Pharmacist Craig Sicinski of Orlando Pharmacy is in-line with our mission to develop the most effective and efficient delivery systems. With Orlando Pharmacy, we are taking our first steps into the pharmaceutical marketplace.”

“We are excited to explore the possibilities for our technologies and processes in the life sciences space and to have our technologies and delivery systems used in the creation of compounded pharmaceutical products  by the pharmacists at Orlando Pharmacy, an experienced cGMP facility. We look forward to a long and rewarding relationship with Mr. Sicinski and his team at Orlando Pharmacy”, said Mr. Ward.

Orlando Pharmacy is a USP 797 compliant pharmacy that has been serving the Orlando community for more than 60 years. Orlando Pharmacy is designated as a Good Neighbor Pharmacy, a network of more than 4,5000 independent pharmacies.  Orlando Pharmacy prides themselves on their reputation for credibility, integrity, and always going the extra mile to meet the needs of its customers and patients.”

Nutralife Biosciences, Inc. operates a multifaceted life sciences company. Since 2013, NutraLife’s manufacturing facility has been registered with the FDA and operated in accordance with the GMP standard. The Company manufactures and distributes private label and branded nutraceutical and wellness products. Through its subsidiaries, Precision Analytic Testing, Inc., and PhytoChem Technologies, Inc., the Company provides bulk material analytical, identity, potency and purity testing of raw hemp, hemp cultivation, raw bulk material extraction and processing. In February of 2019, the Company’s subsidiary, NutraDerma Technologies, Inc. acquired its first product, a patented all natural dermal patch designed to ward off insects including mosquitoes.

NutraLife Sciences is a fully reporting company with a class of securities registered with the U.S. Securities and Exchange Commission (“SEC”). NLBS recently announced its financial results for the three (3) and nine (9) month period ended September 30, 2018 with revenue of $1,062,146 and $2,870,462 respectively compared to $652,385 and $1,027,727 for the three (3) and nine (9) month period ended September 30, 2017. NLBS’s filings with the SEC can be viewed at www.sec.gov. NLBS’s CBD products and information about the company’s direct sales program can be found online at www.nutrahempcbd.com and by following the company on Instagram.

* These statements have not been evaluated by the Food and Drug Administration.

* This product is not intended to diagnose, treat, cure or prevent any disease.

Forward-Looking Statements

This communication from NutraLife BioSciences, Inc. (the “Company”) contains statements of a forward-looking nature. These statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. You can identify these forward-looking statements by words or phrases such as “may,” “will,” “except,” “anticipate,” “aim,” “estimate,” “intend,” “plan,” “believe,” “is/are likely to,” “future” or other similar expressions. The Company has based these forward-looking statements largely on the Company’s current expectations and projections about future events and financial trends that the Company believes may affect Company’s financial condition, results of operations, business strategy, and financial needs. There is no assurance that the Company’s current expectations and projections are accurate. All forward-looking statements in this press release are based on information available to the Company on the date hereof. These statements involve known and unknown risks, uncertainties and other factors that may cause the Company’s actual results to differ materially from those implied by the forward-looking statements. More detailed information about these risk factors are set forth in the Company’s filings with the Securities and Exchange Commission, including, but not limited to, those risks and uncertainties listed in the section entitled “Risk Factors,” in the Company’s Annual Report on Form 10-K with the Securities and Exchange Commission on April 17, 2018. The Company operates in a rapidly evolving environment. New risk factors emerge from time to time, and it is impossible for the Company’s management to predict all risk factors, nor can the Company assess the impact of all factors on Company’s business or the extent to which any factor, or combination of factors, may cause actual results to differ from those contained in any forward-looking statement. The Company does not undertake any obligation to update or revise the forward-looking statements except as required under applicable law.

 

Contact:

 

NutraLife Biosciences, Inc.

6601 Lyons Road

Suite L-6 Coconut Creek

FL  33073 Telephone

Telephone: 888-509-8901

www.Nutralifebiosciences.com

NutraFuels, Inc., to Change its Name to NutraLife BioSciences, Inc. and Proposed Symbol to NLBS

To read this press release on OTCMarkets.com visit:

NutraFuels, Inc., to Change its Name to NutraLife BioSciences, Inc. and Proposed Symbol to NLBS

Coconut Creek, FL, March 05, 2019 (GLOBE NEWSWIRE) — via NEWMEDIAWIRE — NutraFuels, Inc. (the “Company”) is pleased to announce a name change to NutraLife  BioSciences, Inc. and a new stock trading symbol, NLBS.  The Company believes that the name, NutraLife BioSciences better reflects its current and planned future operations. Commencing March 6, 2019, the Company’s common shares will trade with the stock ticker symbol “NLBS”.

The Company is a fully reporting company with a class of securities registered with the U.S. Securities and Exchange Commission (“SEC”). The Company recently announced its financial results for the three (3) and nine (9) month period ended September 30, 2018 with revenue of $1,062,146 and $2,870,462 respectively compared to $652,385 and $1,027,727 for the three (3) and nine (9) month period ended September 30, 2017. NTFU’s filings with the SEC can be viewed at www.sec.gov. NTFU’s CBD products and information about the company’s direct sales program can be found online at www.nutrahempcbd.com and by following the company on Instagram.

* These statements have not been evaluated by the Food and Drug Administration.

* This product is not intended to diagnose, treat, cure or prevent any disease.

Forward-Looking Statements

This communication contains statements of a forward-looking nature. These statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. You can identify these forward-looking statements by words or phrases such as “may,” “will,” “except,” “anticipate,” “aim,” “estimate,” “intend,” “plan,” “believe,” “is/are likely to,” “future” or other similar expressions. The Company has based these forward-looking statements largely on the Company’s current expectations and projections about future events and financial trends that the Company believes may affect Company’s financial condition, results of operations, business strategy, and financial needs. There is no assurance that the Company’s current expectations and projections are accurate. All forward-looking statements in this press release are based on information available to the Company on the date hereof. These statements involve known and unknown risks, uncertainties and other factors that may cause the Company’s actual results to differ materially from those implied by the forward-looking statements. More detailed information about these risk factors are set forth in the Company’s filings with the Securities and Exchange Commission, including, but not limited to, those risks and uncertainties listed in the section entitled “Risk Factors,” in the Company’s Annual Report on Form 10-K with the Securities and Exchange Commission on April 17, 2018. The Company operates in a rapidly evolving environment. New risk factors emerge from time to time, and it is impossible for the Company’s management to predict all risk factors, nor can the Company assess the impact of all factors on Company’s business or the extent to which any factor, or combination of factors, may cause actual results to differ from those contained in any forward-looking statement. The Company does not undertake any obligation to update or revise the forward-looking statements except as required under applicable law.

NutraFuels, Inc. fka NutraLife Biosciences, Inc. Explores New Delivery Systems with Pharmaceutical GMP Manufacturer

To read this press release on OTCMarkets.com visit:

NutraFuels, Inc. fka NutraLife Biosciences, Inc. Explores New Delivery Systems with Pharmaceutical GMP Manufacturer

Coconut Creek, FL, Feb. 28, 2019 (GLOBE NEWSWIRE) — via NEWMEDIAWIRE — NutraFuels, Inc., fka NutraLife Biosciences, Inc. (“the Company” or “NutraFuels”) (OTCQB: NTFU) plans to explore additional options for delivery systems for its nutraceutical and wellness products and pharmaceutical delivery systems.

“We are excited to be exploring our capabilities in the life sciences space by engaging in the research and development of more formulations and enhanced delivery systems with an experienced cGMP pharmaceutical manufacturer,” said Edgar Ward, CEO and Founder of NutraFuels.

The Company plans to explore these various pharmaceutical formulations and delivery systems while utilizing the valuable experience of a cGMP pharmaceutical manufacturer.

The Company manufactures and distributes private label and its own branded products under its NutraHempCBD and NutraSpray brands. The Company’s product development, testing and research are conducted by four chemists under the supervision of Mr. Ward. The Company manufactures 100% of its products at its FDA registered facility in accordance with GMP standards.

The Company is a fully reporting company with a class of securities registered with the U.S. Securities and Exchange Commission (“SEC”). As reported in its Form 8-K filed with the SEC on November 13, 2018, the Company recently announced its financial results for the three (3) and nine (9) month period ended September 30, 2018 with revenue of $1,062,146 and $2,870,462 respectively compared to $652,385 and $1,027,727 for the three (3) and nine (9) month period ended September 30, 2017. The Company’s filings with the SEC can be viewed at www.sec.gov. NTFU’s CBD products and information about the company’s direct sales program can be found online at www.nutrahempcbd.com and by following the company on Instagram.

* These statements have not been evaluated by the Food and Drug Administration.

* This product is not intended to diagnose, treat, cure or prevent any disease.

Forward-Looking Statements

This communication contains statements of a forward-looking nature about NutraFuels, Inc. (the “Company”). These statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. You can identify these forward-looking statements by words or phrases such as “may,” “will,” “except,” “anticipate,” “aim,” “estimate,” “intend,” “plan,” “believe,” “is/are likely to,” “future” or other similar expressions. The Company has based these forward-looking statements largely on the Company’s current expectations and projections about future events and financial trends that the Company believes may affect Company’s financial condition, results of operations, business strategy, and financial needs. There is no assurance that the Company’s current expectations and projections are accurate. All forward-looking statements in this press release are based on information available to the Company on the date hereof. These statements involve known and unknown risks, uncertainties and other factors that may cause the Company’s actual results to differ materially from those implied by the forward-looking statements. More detailed information about these risk factors are set forth in the Company’s filings with the Securities and Exchange Commission, including, but not limited to, those risks and uncertainties listed in the section entitled “Risk Factors,” in the Company’s Annual Report on Form 10-K with the Securities and Exchange Commission on April 17, 2018. The Company operates in a rapidly evolving environment. New risk factors emerge from time to time, and it is impossible for the Company’s management to predict all risk factors, nor can the Company assess the impact of all factors on Company’s business or the extent to which any factor, or combination of factors, may cause actual results to differ from those contained in any forward-looking statement. The Company does not undertake any obligation to update or revise the forward-looking statements except as required under applicable law.